PCM Encore LLC Buys New Position in Elevance Health, Inc. $ELV

Posted by Brenda Bartman on Aug 21st, 2026

PCM Encore LLC purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,536 shares of the company’s stock, valued at approximately $594,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ELV. Trillium Asset Management LLC purchased a new stake in shares of Elevance Health during the second quarter valued at approximately $8,064,000. OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of Elevance Health in the second quarter valued at $701,000. E Fund Management Co. Ltd. acquired a new stake in Elevance Health during the 2nd quarter valued at $614,000. Asahi Life Asset Management CO. LTD. acquired a new stake in Elevance Health during the 2nd quarter valued at $495,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new stake in Elevance Health during the 2nd quarter worth $423,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 0.3%

Shares of NYSE ELV opened at $397.15 on Friday. The stock’s 50 day moving average price is $394.82 and its two-hundred day moving average price is $359.63. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $436.24. The stock has a market capitalization of $86.13 billion, a P/E ratio of 17.65, a PEG ratio of 2.29 and a beta of 0.68. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. The business had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business’s quarterly revenue was up .8% on a year-over-year basis. During the same period in the previous year, the business earned $8.84 EPS. On average, analysts anticipate that Elevance Health, Inc. will post 27.07 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Thursday, September 10th. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Insider Activity at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on ELV. Robert W. Baird boosted their price objective on shares of Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. Barclays lowered their target price on Elevance Health from $480.00 to $457.00 and set an “overweight” rating for the company in a research note on Thursday, July 16th. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup raised Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $395.00 price objective on shares of Elevance Health in a research note on Thursday, July 16th. Fifteen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $440.90.

Read Our Latest Report on Elevance Health

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.